File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy

TitlePrognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy
Authors
KeywordsChronic epilepsy
Prognostic factors
Retention
Topiramate
Issue Date2000
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.epilepsia.com/
Citation
Epilepsia, 2000, v. 41 n. 3, p. 338-341 How to Cite?
AbstractPurpose: To determine the long-term retention rate of topiramate (TPM) therapy in patients with chronic epilepsy and to identify the relevant prognostic factors that influence retention. Methods: All patients with chronic epilepsy (n = 393) prescribed TPM between October 1, 1995, and December 31, 1998, at a tertiary referral centre for epilepsy were analysed. The retention rate for TPM was calculated by using Kaplan-Meier survival analysis, and the prognostic factors influencing retention were analysed by using Cox regression. Results: Of patients prescribed TPM, 30% continued taking the drug beyond 3 years. Discontinuation was mainly due to adverse events and lack of efficacy. Use of more than one new concurrent antiepileptic drug (AED) and lower maximal daily doses were more likely to result in treatment discontinuation due to adverse events. Older age at onset of epilepsy, a history of having previously taken more than one new AED [lamotrigine (LTG), gabapentin (GBP), or vigabatrin (VGB)], and lower maximal daily doses were more likely to lead to discontinuation due to lack of efficacy. Conclusions: A third of patients with chronic epilepsy started on TPM therapy will continue on treatment for >3 years. Absence of learning disabilities, late age at onset of seizures, previous use of more than one new AED, two or more concurrent AED use, and low maximal daily doses of TPM are more likely to result in discontinuation of medication. These factors should be taken into account when considering the use of TPM for the treatment of chronic epilepsy.
Persistent Identifierhttp://hdl.handle.net/10722/132916
ISSN
2015 Impact Factor: 4.706
2015 SCImago Journal Rankings: 2.579
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLhatoo, SDen_HK
dc.contributor.authorWong, ICKen_HK
dc.contributor.authorSander, JWASen_HK
dc.date.accessioned2011-04-04T07:57:58Z-
dc.date.available2011-04-04T07:57:58Z-
dc.date.issued2000en_HK
dc.identifier.citationEpilepsia, 2000, v. 41 n. 3, p. 338-341en_HK
dc.identifier.issn0013-9580en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132916-
dc.description.abstractPurpose: To determine the long-term retention rate of topiramate (TPM) therapy in patients with chronic epilepsy and to identify the relevant prognostic factors that influence retention. Methods: All patients with chronic epilepsy (n = 393) prescribed TPM between October 1, 1995, and December 31, 1998, at a tertiary referral centre for epilepsy were analysed. The retention rate for TPM was calculated by using Kaplan-Meier survival analysis, and the prognostic factors influencing retention were analysed by using Cox regression. Results: Of patients prescribed TPM, 30% continued taking the drug beyond 3 years. Discontinuation was mainly due to adverse events and lack of efficacy. Use of more than one new concurrent antiepileptic drug (AED) and lower maximal daily doses were more likely to result in treatment discontinuation due to adverse events. Older age at onset of epilepsy, a history of having previously taken more than one new AED [lamotrigine (LTG), gabapentin (GBP), or vigabatrin (VGB)], and lower maximal daily doses were more likely to lead to discontinuation due to lack of efficacy. Conclusions: A third of patients with chronic epilepsy started on TPM therapy will continue on treatment for >3 years. Absence of learning disabilities, late age at onset of seizures, previous use of more than one new AED, two or more concurrent AED use, and low maximal daily doses of TPM are more likely to result in discontinuation of medication. These factors should be taken into account when considering the use of TPM for the treatment of chronic epilepsy.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.epilepsia.com/en_HK
dc.relation.ispartofEpilepsiaen_HK
dc.subjectChronic epilepsyen_HK
dc.subjectPrognostic factorsen_HK
dc.subjectRetentionen_HK
dc.subjectTopiramateen_HK
dc.titlePrognostic factors affecting long-term retention of topiramate in patients with chronic epilepsyen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, ICK: wongick@hku.hken_HK
dc.identifier.authorityWong, ICK=rp01480en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid10714407-
dc.identifier.scopuseid_2-s2.0-0034008032en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034008032&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume41en_HK
dc.identifier.issue3en_HK
dc.identifier.spage338en_HK
dc.identifier.epage341en_HK
dc.identifier.isiWOS:000085665200012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLhatoo, SD=35482407900en_HK
dc.identifier.scopusauthoridWong, ICK=7102513915en_HK
dc.identifier.scopusauthoridSander, JWAS=7202898360en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats